
|Videos|November 18, 2021
A urologist gives his take on PSMA in prostate cancer
Author(s)Urology Times staff
“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.
Advertisement
In this video, Jason M. Hafron, MD, shares why he thinks PSMA is “disruptive technology” in prostate cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan. He was speaking at the 2021 LUGPA annual meeting.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Treatment Selection in Advanced Prostate Cancer
3
Pearls & Perspectives: Leadership and Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, MBA
4
Advice for the Next Generation of Urologists in mCSPC Management
5






